WO2026078631A2 - Récepteurs antigéniques chimériques activables - Google Patents

Récepteurs antigéniques chimériques activables

Info

Publication number
WO2026078631A2
WO2026078631A2 PCT/IB2025/060249 IB2025060249W WO2026078631A2 WO 2026078631 A2 WO2026078631 A2 WO 2026078631A2 IB 2025060249 W IB2025060249 W IB 2025060249W WO 2026078631 A2 WO2026078631 A2 WO 2026078631A2
Authority
WO
WIPO (PCT)
Prior art keywords
car
polypeptide chain
seq
antigen
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2025/060249
Other languages
English (en)
Inventor
Melita IRVING
Greta Giordano ATTIANESSE
George Coukos
Bruno Correia
Sailan SHUI
Leo Scheller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ecole Polytechnique Federale de Lausanne EPFL
Universite de Lausanne
Ludwig Institute for Cancer Research Ltd
Centre Hospitalier Universitaire Vaudois CHUV
Original Assignee
Ecole Polytechnique Federale de Lausanne EPFL
Universite de Lausanne
Ludwig Institute for Cancer Research Ltd
Centre Hospitalier Universitaire Vaudois CHUV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecole Polytechnique Federale de Lausanne EPFL, Universite de Lausanne, Ludwig Institute for Cancer Research Ltd, Centre Hospitalier Universitaire Vaudois CHUV filed Critical Ecole Polytechnique Federale de Lausanne EPFL
Publication of WO2026078631A2 publication Critical patent/WO2026078631A2/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/24—Dimerizable CARs; CARs with adapter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des récepteurs antigéniques chimériques (CAR) activables et leur utilisation pour un traitement.
PCT/IB2025/060249 2024-10-10 2025-10-09 Récepteurs antigéniques chimériques activables Pending WO2026078631A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463705954P 2024-10-10 2024-10-10
US63/705,954 2024-10-10

Publications (1)

Publication Number Publication Date
WO2026078631A2 true WO2026078631A2 (fr) 2026-04-16

Family

ID=97752586

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2025/060249 Pending WO2026078631A2 (fr) 2024-10-10 2025-10-09 Récepteurs antigéniques chimériques activables

Country Status (1)

Country Link
WO (1) WO2026078631A2 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048549A1 (en) 2003-01-21 2005-03-03 Liangxian Cao Methods and agents for screening for compounds capable of modulating gene expression
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US20090142354A1 (en) 2006-12-14 2009-06-04 Regeneron Pharmaceuticals, Inc. Human antibodies to human delta like ligand 4
US20110027286A1 (en) 2009-07-29 2011-02-03 Regeneron Pharmaceuticals, Inc. High Affinity Human Antibodies to Human Angiopoietin-2
US20110286980A1 (en) 2010-05-21 2011-11-24 Brenner Malcolm K Methods for inducing selective apoptosis
WO2018231759A1 (fr) 2017-06-12 2018-12-20 Obsidian Therapeutics, Inc. Compositions de pde5 et méthodes d'immunothérapie
WO2020223279A1 (fr) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. Anticorps vectorisés (vab) et leurs utilisations
US20210113615A1 (en) 2018-04-13 2021-04-22 Ludwig Institute For Cancer Research Ltd. Heterodimeric inactivatable chimeric antigen receptors
US20230141511A1 (en) 2019-12-20 2023-05-11 Ludwig Institute For Cancer Research Ltd Car-t cell therapy targeting ngcgm3

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US20050048549A1 (en) 2003-01-21 2005-03-03 Liangxian Cao Methods and agents for screening for compounds capable of modulating gene expression
US20090142354A1 (en) 2006-12-14 2009-06-04 Regeneron Pharmaceuticals, Inc. Human antibodies to human delta like ligand 4
US20110027286A1 (en) 2009-07-29 2011-02-03 Regeneron Pharmaceuticals, Inc. High Affinity Human Antibodies to Human Angiopoietin-2
US20110286980A1 (en) 2010-05-21 2011-11-24 Brenner Malcolm K Methods for inducing selective apoptosis
WO2018231759A1 (fr) 2017-06-12 2018-12-20 Obsidian Therapeutics, Inc. Compositions de pde5 et méthodes d'immunothérapie
US20200101142A1 (en) 2017-06-12 2020-04-02 Obsidian Therapeutics, Inc. Pde5 compositions and methods for immunotherapy
US20230074330A1 (en) 2017-06-12 2023-03-09 Obsidian Therapeutics, Inc. Pde5 compositions and methods for immunotherapy
US20210113615A1 (en) 2018-04-13 2021-04-22 Ludwig Institute For Cancer Research Ltd. Heterodimeric inactivatable chimeric antigen receptors
WO2020223279A1 (fr) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. Anticorps vectorisés (vab) et leurs utilisations
US20230075314A1 (en) 2019-04-29 2023-03-09 Voyager Therapeutics, Inc. VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
US20230141511A1 (en) 2019-12-20 2023-05-11 Ludwig Institute For Cancer Research Ltd Car-t cell therapy targeting ngcgm3

Non-Patent Citations (74)

* Cited by examiner, † Cited by third party
Title
"Synthetic Protein Switches", vol. 3, 2017, pages: 25
"UniProt", Database accession no. P10415
ARTHRITIS RES. & THER., vol. 14, no. 5, 2012, pages 1
BJERREGAARD-ANDERSEN, K., SCI. REP., 2018, pages 10836
BLUESTONE ET AL., PNAS, vol. 101, 2004, pages 14622 - 14626
BRENTJENS RJDAVILA MLRIVIERE I ET AL.: "CD 19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia", SCI TRANSL MED, vol. 5, 2013, pages 177 - 138
CAPPELL KM, AND KOCHENDERFER JN: "Long-term outcomes following CAR T cell therapy: what we know so far", NAT REV CLIN ONCOL, vol. 20, no. 6, 2023, pages 359 - 71
CARBONNEAU SSHARMA SPENG LRAJAN VHAINZL DHENAULT M ET AL.: "An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity", CELL CHEM BIOL, vol. 28, no. 6, 2021, pages 802 - 12
CATHCART, LAB. INVEST., vol. 54, 1986, pages 26
CELL, vol. 171, no. 7, 2017, pages 1471
COHN ET AL., J. EXP. MED., 1997, pages 1861737 - 1747
COURTENAY ET AL., NATURE, vol. 283, 1980, pages 665
CROFFORD L. J.WILDER R. L. ET AL.: "Arthritis and Allied Conditions: A Textbook of Rheumatology", 1993, article "Arthritis and Autoimmunity in Animals"
DEL BUFALO FDE ANGELIS BCARUANA IDEL BALDO GDE IORIS MASERRA A ET AL.: "GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma", N ENGL J MED, vol. 388, no. 14, 2023, pages 1284 - 95
DESELM CPALOMBA MLYAHALOM JHAMIEH MEYQUEM JRAJASEKHAR VK ET AL.: "Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape", MOL THER, vol. 26, no. 11, 2018, pages 2542 - 52
FEDOROV, V.D.THEMELI, M.SADELAIN, M.: "PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses", SCI TRANSL MED, vol. 5, 2013, pages 215 - 172
FEGAN A, WHITE B, CARLSON JC, AND WAGNER CR: "Chemically controlled protein assembly:techniques and applications", CHEM REV., vol. 110, no. 6, 2010, pages 3315 - 36
FLANDERS ET AL., AUTOIMMUNITY, vol. 29, 1999, pages 235 - 246
FOSTER, SEMIN. NEPHROL., vol. 19, 1999, pages 12 - 24
GARGETT TBROWN MP: "The inducible caspase-9 suicide gene system as a ''safety switch'' to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells", FRONT PHARMACOL, vol. 5, 2014, pages 235
GENNARO ET AL.: "Remington's The Science and Practice of Pharmacy", 2000, LIPPINCOTT WILLIAMS AND WILKINS
GIORDANO ATTIANESE GMPASH SIRVING M: "Coengineering specificity, safety, and function into T cells for cancer immunotherapy", IMMUNOL REV, 2023
GIORDANO-ATTIANESE GGAINZA PGRAY-GAILLARD ECRIBIOLI ESHUI SKIM S ET AL.: "A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy", NAT BIOTECHNOL., vol. 38, no. 4, 2020, pages 426 - 32
HERRERA FGRONET COCHOA DE OLZA MBARRAS DCRESPO IANDREATTA M ET AL.: "Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy", CANCER DISCOV, vol. 12, no. 1, 2022, pages 108 - 33
HILL ZBMARTINKO AJNGUYEN DPWELLS JA: "Human antibody-based chemically induced dimerizers for cell therapeutic applications", NAT CHEM BIOL., vol. 14, no. 2, 2018, pages 112 - 7
HOLMDAHL, R., CURR. BIOL., vol. 15, 1999, pages 528 - 530
ISAACS ET AL., RHEUMATOLOGY, vol. 40, 2001, pages 724 - 738
JAN ET AL., SCI TRANSL MED, vol. 13, no. 575, 6 January 2021 (2021-01-06), pages 6295
JAN M, SPERLING AS, AND EBERT BL: "Cancer therapies based on targeted protein degradation- lessons learned with lenalidomide", NAT REV CLIN ONCOL, vol. 18, no. 7, 2021, pages 401 - 17
JAN MSCARFO ILARSON RCWALKER ASCHMIDTS AGUIRGUIS AA ET AL.: "Reversible ON-and OFF-switch chimeric antigen receptors controlled by lenalidomide", SCI TRANSL MED, vol. 13, no. 575, 2021, pages 6295
JONES BSLAMB LSGOLDMAN FDI STASI A: "Improving the safety of cell therapy products by suicide gene transfer", FRONT PHARMACOL, vol. 5, 2014, pages 254
JOURN. CLIN. INVEST., vol. 122, no. 6, 2012, pages 2257 - 66
KALE JOSTERLUND EJANDREWS DW: "BCL-2 family proteins: changing partners in the dance towards death", CELL DEATH DIFFER, vol. 25, no. 1, 2018, pages 65 - 80
KIM ET AL., SCAND. J. GASTROENTROL., vol. 27, 1992, pages 529 - 537
KLAMPATSA, A. ET AL., EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 21, no. 4, pages 473 - 486
KOHLHAPP FJ, HARIBHAI D, MATHEW R, DUGGAN R, ELLIS PA, WANG R: "Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade", CANCER DISCOV, vol. 11, no. 1, 2021, pages 68 - 79
KOHLHAPP FJHARIBHAI DMATHEW R ET AL.: "Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade", CANCER DISCOV, vol. 11, no. 1, January 2021 (2021-01-01), pages 68 - 79
KROGH ET AL., BIOCHIMIE, vol. 81, 1999, pages 511 - 515
LANITIS ECOUKOS GIRVING M: "All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy", CURR OPIN BIOTECHNOL, vol. 65, 2020, pages 75 - 87
LANITIS EDANGAJ DIRVING MCOUKOS G: "Mechanisms regulating T-cell infiltration and activity in solid tumors", ANN ONCOL, vol. 28, 2017, pages 8 - 32
LANITIS EROTA GKOSTI PRONET CSPILL ASEIJO B ET AL.: "Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression", J EXP MED, vol. 218, no. 2, 2021
LANITIS, E. ET AL.: "Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo", CANCER IMMUNOL RES, vol. 1, 2013, pages 43 - 53
LEE YGGURUPRASAD PGHILARDI GPAJARILLO RSAUTER CTPATEL R ET AL.: "Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer", CANCER DISCOV, vol. 12, no. 10, 2022, pages 2372 - 91
LEUKEMIA & LYMPHOMA, vol. 18, no. 5-6, 1995, pages 385 - 397
LEUNG WHGAY JMARTIN UGARRETT TEHORTON HMCERTO MT ET AL.: "Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization", JCI INSIGHT, vol. 5, no. 11, 2019
LIN Q ET AL., FRONT. ONCOL, vol. 11, pages 694941
LOPEZ J, AND TAIT SW: "Mitochondrial apoptosis: killing cancer using the enemy within", J CANCER, vol. 112, no. 6, 2015, pages 957 - 62
MAJZNER, R.G. ET AL., NATURE, vol. 603, 2022, pages 934 - 941
MARSDEN VSSTRASSER A: "Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more", ANNU REV IMMUNOL, vol. 21, 2003, pages 71 - 105
MAUDE SLFREY NSHAW PA ET AL.: "Chimeric antigen receptor T cells for sustained remissions in leukemia", N ENGL J MED, vol. 371, 2014, pages 1507 - 1517
MAUS MVGRUPP SAPORTER DLJUNE CH: "Antibody-modified T cells: CARs take the front seat for hematologic malignancies", BLOOD, vol. 123, 2014, pages 2625 - 2635
MIYAMOTO TDEROSE RSUAREZ AUENO TCHEN MSUN TP ET AL.: "Rapid and orthogonal logic gating with a gibberellin-induced dimerization system", NAT CHEM BIOL, vol. 8, no. 5, 2012, pages 465 - 70
MOL. THER., vol. 25, no. 5, 26 April 2017 (2017-04-26), pages 1117 - 1124
MORGAN RAYANG JCKITANO M ET AL.: "Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2", MOL THER, vol. 18, 2010, pages 843 - 851
NATURE REVIEWS RHEUMATOLOGY, vol. 7, no. 3, 2011, pages 170 - 178
NEW ENGLAND J. MED., vol. 365, no. 8, 2011, pages 725 - 33
RAJAN, S.CHOI, M.BAEK, K.YOON, H.S. ET AL.: "Bh3 induced conformational changes in Bcl-Xl revealed by crystal structure and comparative analysis", PROTEINS, vol. 83, 2015, pages 1262 - 1272
SALZER B, SCHUELLER CM, ZAJC CU, PETERS T, SCHOEBER MA, KOVACIC B: "11", NAT COMMUN, no. 1, 2020, pages 4166
SCHELLEKENS H.: "Factors influencing the immunogenicity of therapeutic proteins", NEPHROL DIAL TRANSPLANT, vol. 20, 2005, pages 3 - 9
SENTMAN ET AL., CANCER J, vol. 20, no. 2, 2014, pages 156 - 159
SHAMAS-DIN AKALE JLEBER BANDREWS DW: "Mechanisms of action of Bcl-2 family proteins", COLD SPRING HARB PERSPECT BIOL, vol. 5, no. 4, 2013, pages 008714
SOUBRANE ET AL., BLOOD, vol. 81, no. 1, 1993, pages 15 - 19
SOUERS, A.J., LEVERSON, J.D., BOGHAERT, E.R., ACKLER, S.L., CATRON, N.D., CHEN, J., DAYTON, B.D., DING, H., ENSCHEDE, S.H., FAIRBR: "ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets", NAT MED, vol. 19, 2013, pages 202 - 208
STANTON BZCHORY EJCRABTREE GR: "mically induced proximity in biology and medicine", SCIENCE, vol. 359, 2018, pages 6380
STRAATHOF ET AL., BLOOD, vol. 105, no. 11, 2005, pages 4247 - 4254
STROBER, DIG. DIS. SCI., vol. 30, 1985, pages 3 - 10
TRENTHORN ET AL., J. EXP. MED., vol. 146, 1977, pages 857
WEBER EWPARKER KRSOTILLO ELYNN RCANBUNATHAN HLATTIN J ET AL.: "Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling", SCIENCE, vol. 372, 2021, pages 6537
WOLF B, ZIMMERMANN S, ARBER C, IRVING M, TRUEB L, AND COUKOS G: "Safety and Tolerability of Adoptive Cell Therapy in Cancer", DRUG SAF, 2019
WU CYROYBAL KTPUCHNER EMONUFFER JLIM WA: "Remote control of therapeutic T cells through a small molecule-gated chimeric receptor", SCIENCE, vol. 350, no. 6258, 2015, pages 4077
WU ET AL., J. BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432
WYPYCH ET AL., JBC, vol. 283, no. 23, 2008, pages 16194 - 16205
ZAJC CUDOBERSBERGER MSCHAFFNER IMLYNEK GPIIHRINGER DSALZER B ET AL.: "A conformation-specific ON-switch for controlling CAR T cells with an orally available drug", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 117, no. 26, 2020, pages 14926 - 35
ZAMVIL ET AL., ANN. REV, IMMUNOL., vol. 8, 1990, pages 579

Similar Documents

Publication Publication Date Title
US12528847B2 (en) Heterodimeric inactivatable chimeric antigen receptors
JP7548950B2 (ja) キメラ抗原受容体およびその使用方法
JP7475088B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
CN112840019B (zh) 与调节克雷布斯循环的反式代谢分子组合的嵌合抗原受体多肽及其治疗用途
CN105683214B (zh) 触发针对多种肿瘤的抗体依赖细胞毒性的嵌合受体
CN111601823B (zh) 用car-t或car-nk细胞在癌症治疗中靶向lilrb4
AU2021221880A1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
CN112638402A (zh) 与增强葡萄糖输入的反式代谢分子组合的嵌合受体及其治疗用途
AU2014225788A1 (en) Engager cells for immunotherapy
JP2026500718A (ja) Ｂ７－ｈ３を標的とする抗体または抗体断片、およびキメラ抗原受容体免疫細胞療法の分野におけるその使用
EP4408982A1 (fr) Polypeptides récepteurs chimériques en combinaison avec des molécules de métabolisme trans qui réorientent des métabolites de glucose hors de la voie de glycolyse et leurs utilisations thérapeutiques
AU2021246112A1 (en) Enhancement of adoptive cell transfer
WO2022060806A1 (fr) Compositions et procédés pour l'expression de récepteurs antigéniques chimériques anti-bcma ayant une il15 régulée par petites molécules dans des cellules t
WO2021259237A1 (fr) LYMPHOCYTES T γδT GÉNÉTQUEMENT MODIFIÉS POUR IMMUNOTHÉRAPIE
AU2017371514B2 (en) Improved NK-based cell therapy
EP4572787A1 (fr) Cellules immunitaires génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec de multiples molécules du métabolisme trans et leurs utilisations thérapeutiques
WO2023230534A2 (fr) Utilisation de constructions de fusion pour une thérapie par lymphocytes t indépendante de l'il-2
JP2026021420A (ja) 二重ｃａｒ－ｔ細胞
US20230141511A1 (en) Car-t cell therapy targeting ngcgm3
CN115925985A (zh) Car-t细胞及其在非小细胞肺癌治疗中的应用
RU2839662C1 (ru) Т-клетки с двумя химерными антигенными рецепторами car
KR102739632B1 (ko) 항-cd20 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
US20250041341A1 (en) Polypeptides targeting cd105+ cancers
CN119894923A (zh) 包含tmigd2共刺激结构域的嵌合抗原受体及其相关使用方法
HK40013541A (en) Synthetic immune receptors and methods of use thereof